Skip to main content

NASDAQ:KDMN - Kadmon Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.75
  • Forecasted Upside: 236.41 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$3.79
▲ +0.14 (3.84%)
1 month | 3 months | 12 months
Get New Kadmon Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KDMN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KDMN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$12.75
▲ +236.41% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Kadmon in the last 3 months. The average price target is $12.75, with a high forecast of $20.00 and a low forecast of $8.00. The average price target represents a 236.41% upside from the last price of $3.79.

Buy

The current consensus among 5 polled investment analysts is to buy stock in Kadmon. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/21/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/19/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/17/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/26/2021HC WainwrightReiterated RatingBuy$20.00High
i
3/11/2021Raymond JamesBoost Price TargetOutperform$9.00 ➝ $10.00Low
i
3/5/2021Raymond JamesBoost Price TargetOutperform$9.00 ➝ $10.00High
i
2/10/2021HC WainwrightReiterated RatingBuy$25.00Low
i
11/11/2020MizuhoInitiated CoverageBuy$13.00Medium
i
11/10/2020MizuhoInitiated CoverageBuy$13.00High
i
11/9/2020HC WainwrightReiterated RatingBuy$25.00High
i
Rating by Andrew Fein at HC Wainwright
10/9/2020Cantor FitzgeraldReiterated RatingOverweightMedium
i
Rating by A. Young at Cantor Fitzgerald
10/1/2020Raymond JamesReiterated RatingBuyMedium
i
Rating by Steven Seedhouse at Raymond James
9/22/2020OppenheimerReiterated RatingBuy$8.00High
i
8/7/2020Raymond JamesBoost Price TargetOutperform$9.00 ➝ $10.00High
i
Rating by Steven Seedhouse at Raymond James
6/28/2020HC WainwrightReiterated RatingBuy$25.00Low
i
Rating by Andrew Fein at HC Wainwright
5/22/2020HC WainwrightReiterated RatingBuy$25.00Low
i
Rating by Andrew Fein at HC Wainwright
5/19/2020Raymond JamesInitiated CoverageOutperform$7.00High
i
5/7/2020OppenheimerReiterated RatingBuy$8.00Medium
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
3/5/2020OppenheimerReiterated RatingBuy$8.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
2/26/2020HC WainwrightReiterated RatingBuy$25.00Low
i
1/10/2020Nomura SecuritiesInitiated CoverageBuy$10.00High
i
11/12/2019Cantor FitzgeraldBoost Price TargetOverweight$8.00 ➝ $10.00High
i
Rating by E. Merle at Cantor Fitzgerald
9/5/2019Cantor FitzgeraldInitiated CoverageOverweight$8.00Low
i
Rating by E. Merle at Cantor Fitzgerald
6/26/2019OppenheimerInitiated CoverageOutperform$6.00High
i
3/12/2019HC WainwrightReiterated RatingBuy$25.00High
i
2/26/2019CitigroupUpgradeNeutral ➝ Buy$2.77Low
i
11/12/2018HC WainwrightReiterated RatingBuy$25.00High
i
Rating by Andrew Fein at HC Wainwright
10/17/2018WBB SecuritiesUpgradeSell ➝ Hold$2.90Medium
i
8/13/2018HC WainwrightSet Price TargetBuy$25.00Medium
i
Rating by Andrew Fein at HC Wainwright
3/9/2018HC WainwrightReiterated RatingBuy$25.00High
i
Rating by A. Fein at HC Wainwright
2/13/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Positive$7.00 ➝ $9.00High
i
2/13/2018Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$16.00High
i
12/15/2017HC WainwrightReiterated RatingBuy$25.00Low
i
Rating by A. Fein at HC Wainwright
11/17/2017HC WainwrightReiterated RatingBuy$25.00N/A
i
Rating by A. Fein at HC Wainwright
10/9/2017WBB SecuritiesDowngradeHold ➝ Sell$3.00N/A
i
8/2/2017Piper Jaffray CompaniesSet Price TargetBuy$7.00Medium
i
Rating by Edward Tenthoff at Piper Jaffray Companies
7/14/2017Piper Jaffray CompaniesReiterated RatingBuy$7.00Medium
i
Rating by Edward Tenthoff at Piper Jaffray Companies
6/26/2017HC WainwrightReiterated RatingBuy$25.00High
i
3/27/2017CitigroupLower Price TargetNeutral$6.00 ➝ $4.00High
i
3/23/2017Piper Jaffray CompaniesReiterated RatingOverweight$36.10 ➝ $23.00Low
i
Rating by Edward Tenthoff at Piper Jaffray Companies
3/16/2017WBB SecuritiesUpgradeSell ➝ Hold$3.25Medium
i
3/14/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$7.00High
i
2/1/2017HC WainwrightReiterated RatingBuy$25.00N/A
i
11/21/2016JMP SecuritiesReiterated RatingBuyN/A
i
Rating by michael king at JMP Securities
11/10/2016Jefferies Financial GroupReiterated RatingBuy$12.00 ➝ $10.00N/A
i
8/22/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by A. Fein at HC Wainwright
8/22/2016JMP SecuritiesInitiated CoverageOutperform$16.00N/A
i
8/22/2016Jefferies Financial GroupInitiated CoverageBuy$12.00 ➝ $12.00N/A
i
8/22/2016HC WainwrightInitiated CoverageBuy$25.00N/A
i
8/22/2016CitigroupInitiated CoverageNeutral$12.00N/A
i
8/1/2016WBB SecuritiesInitiated CoverageSell$7.50N/A
i
(Data available from 5/18/2016 forward)
Kadmon logo
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York.
Read More

Today's Range

Now: $3.79
$3.66
$3.84

50 Day Range

MA: $3.84
$3.57
$4.16

52 Week Range

Now: $3.79
$3.14
$5.73

Volume

19,359 shs

Average Volume

3,281,476 shs

Market Capitalization

$651.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Kadmon?

The following Wall Street sell-side analysts have issued research reports on Kadmon in the last twelve months: Cantor Fitzgerald, HC Wainwright, Mizuho, Oppenheimer Holdings Inc., Raymond James, and Zacks Investment Research.
View the latest analyst ratings for KDMN.

What is the current price target for Kadmon?

4 Wall Street analysts have set twelve-month price targets for Kadmon in the last year. Their average twelve-month price target is $12.75, suggesting a possible upside of 249.3%. HC Wainwright has the highest price target set, predicting KDMN will reach $20.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $8.00 for Kadmon in the next year.
View the latest price targets for KDMN.

What is the current consensus analyst rating for Kadmon?

Kadmon currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KDMN will outperform the market and that investors should add to their positions of Kadmon.
View the latest ratings for KDMN.

What other companies compete with Kadmon?

How do I contact Kadmon's investor relations team?

Kadmon's physical mailing address is 450 East 29th Street, New York NY, 10016. The company's listed phone number is 833 900 5366 and its investor relations email address is [email protected] The official website for Kadmon is www.kadmon.com.